| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 4,036,868 | |||
| Accounts receivable, net | 863,281 | |||
| Inventories, net | 531,687 | |||
| Prepaid expenses and other current assets | 232,641 | |||
| Total current assets | 5,664,477 | |||
| Property, plant and equipment, net | 1,628,114 | |||
| Operating lease right-of-use assets | 140,217 | |||
| 2025 (remainder of year) | 2,090 | |||
| 2026-Cost Of Sales | 8,272 | |||
| 2026-Selling General And Administrative Expenses | 67 | |||
| 2026 | 8,339 | |||
| 2027 | 8,339 | |||
| 2029 | 8,339 | |||
| 2030 and thereafter | 28,135 | |||
| Intangible assets, net | 63,581 | |||
| Other non-current assets | 136,197 | |||
| Total non-current assets | 1,968,109 | |||
| Total assets | 7,632,586 | |||
| Accounts payable | 383,676 | |||
| Accrued expenses and other payables | 1,001,661 | |||
| Tax payable | 11,219 | |||
| Operating lease liabilities, current portion | 15,732 | |||
| Research and development cost share liability, current portion | 90,596 | |||
| Sale of future royalty liability, current portion | 52,245 | |||
| Short-term debt | 813,296 | |||
| Total current liabilities | 2,368,425 | |||
| Long-term debt | 139,571 | |||
| Sale of future royalty liability, non-current portion | 832,755 | |||
| Operating lease liabilities, non-current portion | 51,387 | |||
| Deferred tax liabilities | 47,066 | |||
| Research and development cost share liability, non-current portion | 0 | |||
| Other long-term liabilities | 64,056 | |||
| Total non-current liabilities | 1,134,835 | |||
| Total liabilities | 3,503,260 | |||
| Ordinary shares, 0.0001 par value per share 1,540,975,898 and 1,387,367,704 shares issued and 1,438,083,590 and 1,387,367,704 shares outstanding as of september 30, 2025 and december 31, 2024, respectively | 144 | |||
| Additional paid-in capital | 12,616,844 | |||
| Accumulated other comprehensive loss | -101,257 | |||
| Accumulated deficit | -8,386,405 | |||
| Total shareholders equity | 4,129,326 | |||
| Total liabilities and shareholders equity | 7,632,586 | |||
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)